Adrian Bot
Vice President of Translational Medicine
Kite, a Gilead Company

Adrian Bot, M.D., Ph.D. is the Vice President of Translational Medicine at Kite, a Gilead Company, developing genetically engineered cell products for oncology indications. Dr. Bot obtained his M.D. in Romania in 1993 and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998.  Subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla. Prior to his appointment as Chief Scientific Officer at Kite Pharma in 2011 and then Vice President of Translational Medicine, Dr. Bot served in various senior R&D management positions at MannKind Corp and Alliance Pharmaceutical Corp.

Day Two

Wednesday 26th February 2020

9:30 am | Determinants of Durable Response Upon Treatment with Axi-cel

Alessandra Cesano
Chief Medical Officer

Alessandra Cesano, MD, PhD has recently joined ESSA as Chief Medical Officer. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 100 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.

Ali Mohamad
Vice President CMC

Ali Mohamed, PhD, Vice President, CMC, Immatics US Inc. Formerly the senior director of manufacturing operations/ manufacturing development at Caladrius PCT (Now Hitachi Chemical Advanced Therapeutics Solutions). Dr. Mohamed has nearly 20 years of experience in process development and GMP manufacturing of regenerative medicine, cell and gene therapy products at various CMOs and clinical stage companies including Lonza, Osiris Therapeutics, and AlloCure. The speaker holds a PhD in Molecular Pharmacology from Medical College of Ohio and postdoctoral fellowship in neuroscience and neurobiology from the Georgetown University.

Alice Brown
Vice President of Research
GammaDelta Therapeutics

Alice Brown is Vice President of Research at GammaDelta Therapeutics leading a team developing Vd1 gd T cells as a novel cell therapy approach for tackling solid tumours and hematologic malignancies. Prior to GammaDelta, Alice spent 7 years with PsiOxus Therapeutics as Director of Biology. Alice has a PhD in Biochemistry and carried out her post-doctoral research in Prof. Dan Davis’ Lab at Imperial College London studying the basic biology and interactions of human NK cells

Annie Hubert
Senior Director, Section & Public Policy
Alliance for Regenerative Medicine

Blake Aftab
Vice President and Head of Preclinical Science and Translational Medicine
Atara Biotherapeutics

Blake T. Aftab, PhD is Vice President and Head of Preclinical Science and Translational Medicine at Atara Biotherapeutics. Dr. Aftab leads cell therapy discovery, research, and translational evaluation for off-the-shelf cell therapies covering oncology, infectious disease, and autoimmune conditions. He has over 15 years experience in academic, biotech and pharmaceutical industries developing multiple therapeutic modalities including small molecule, biologics, antibody-drug conjugates and cell therapies. He conducted his doctoral training in Pharmacology and Drug Development at The Johns Hopkins University School of Medicine and received his Bachelors in Pharmacology and Drug Discovery from The University of California, Santa Barbara.

Cedrik Britten
VP & Head of Oncology Cell Therapy Research Unit

Cedrik is a physician and immunologist working in the field of Immuno-Oncology since 1998. From 2001 to 2008 he worked in haematology and blood transfusion departments and conducted translational research on tumour-specific T cells and anti-cancer vaccines trials. Cedrik joined BioNTech AG in 2008 where he drove the company’s growth to a mid-sized enterprise of 250 FTE. As Vice President R&D his translational team was the first to test highly personalized mutanome vaccines in melanoma patients. Cedrik joined GSK in 2015 and is heading the Oncology Cell Therapy Research Unit (OCT RU). The current R&D activities cover the non-clinical and clinical development of TCR-T & CAR-T cells, technologies to enhance patient benefit of engineered lymphocytes in solid cancer, innovative ways to supply autologous cell products, and the discovery of new targets for CAR-T cell approaches.

Deborah Morrison
Principal Scientific Advisor
National Institute for Health & Care Excellence

Delfi Krishna
Director, Strategy, Portfolio, Operations, Cell & Gene Therapy Platform

Dolores Schendel

Since the 1970s, Prof. Dr. Dolores Schendel has been researching T cells and their abilities in immunotherapy and has accompanied the scientific and therapeutic turn of era in this field. Prof Schendel served as a University Professor for Immunology at the Ludwig-Maximilian-University, is the author of more than 200 scientific publications, has spent several decades as a scientific review board member in various research organizations such as the German Research Foundation, German Cancer Aid and the European Research Council among others. She is a recipient of the German Federal Order of Merit and the Bavarian Order of Merit and received the 'Deutsche Krebshilfe Preis', the award of the German Cancer Aid. From 1998 - 2013, Prof Schendel was Director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich. Following this, she founded the Trianta Immunotherapies GmbH (today "Medigene Immunotherapies GmbH). With the acquisition by Medigene in 2014, Dolores Schendel became Chief Scientific Officer and, in 2016, also the CEO of the company.

Day One

Tuesday 25th February 2020

8:30 am | Industry Leader's Fireside Chat

Francesco Marincola
Chief Scientific Officer
Refuge Biotechnologies

Dr. Marincola is Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California. He was previously Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications and Clinical and Translational Medicine. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning author of The Wise Men of Pizzo and Cat Behind the Window.

Jen Renwick
VP, Development Operations

  Jen Renwick is Vice President, Development Operations at Adaptimmune LLC, a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer.   She joined the company in 2016 to lead the Clinical Science and Operations function responsible for trial planning and execution.  Jen was instrumental in building the group in the US and EU and initiating Adaptimmune’s first TCR trials in Europe. She has also provided operational oversight and management of the Development function and the integration of Research and Development.   An Oncology Pharmacist by training, she has over 25 years’ experience in the biopharmaceutical sector specialising in clinical development.  Prior to Adaptimmune, she was Head of Global Study Management at Amgen with oversight of Phase 1b-4 trial execution across all therapeutic areas. She was involved in several Regulatory filings of unique oncology products, including treatments for solid tumours and hematologic malignancies, as well as supportive care agents.  During her time at Amgen she also gained Medical Affairs and commercial launch experience at Amgen Europe’s headquarters in Switzerland and led the clinical integration of several small immuno-oncology companies post acquisition.

Hong Ma
SVP, Clinical Development
CARsgen Therapeutics

Dr. Hong MA is a clinical oncologist with 20 years of cancer immunotherapy and orphan drug development experience, including over 15 years of pharmaceutical industry experience. He has in-depth experience in cellular therapy programs in the U.S. and EMA region with 8 IND & CTA approvals. Before joining in CARsgen, he served as the senior medical director & senior director of clinical development at Immatics Biotechnologies GmbH. Prior to this role, he was the director of clinical development at Bellicum Pharmaceutical, Inc. and was the director of clinical operation at Endocyte Pharmaceutical (now the part of Novartis Oncology).

Jacquelyn Awigena-Cook
Associate Director, Regulatory Policy and Intelligence

Jacquelyn is currently Associate Director, Regulatory Policy and Intelligence at Celgene. She has over 12 years of experience in the pharmaceutical industry managing projects, designing processes and leading initiatives aimed at driving regulatory policy advocacy activities that support development of innovative medicines and assessing the impact of regulatory changes on strategy, operations and compliance. Her current area of focus is on regulatory policies impacting Advanced Therapy Medicinal Products (ATMPs) and delivering key regulatory intelligence insights to support project teams in the Hematology – Oncology disease area. She also spent several years’ focusing on the global pharmacovigilance regulatory environment.

John Johnston
Clinical Assessor

John Maher
Immunology Consultant, King’s College London / CSO
Leucid Bio

Dr John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and the Royal Free NHS Foundation Trust, at Barnet Hospital.

Day Two

Wednesday 26th February 2020

8:45 am | Chair's Opening Remarks

Kai Pinkernell

Dr. Kai Pinkernell is responsible for the clinical advancement of Medigene's immunotherapy platforms since February 2016. In April 2018, he was appointed to the Executive Management Board of the Company as Chief Medical Officer (CMO) and Chief Development Officer (CDO). Dr. Pinkernell has acquired long-term expertise in worldwide clinical development, clinical marketing and clinical sales as well as automation and GMP production of cellular therapies. Prior to joining Medigene, he held leading positions at Miltenyi Biotech GmbH, Bergisch Gladbach, Germany, most recently as Global Head of Clinical Business and Head of Clinical Development. Previously, Dr. Pinkernell was with Cytori Therapeutics Inc., San Diego, USA, as Senior Director of Regenerative Cell Technology.

Lothar Germeroth
Juno Therapeutics

Lothar Germeroth is Senior Vice President at Juno Therapeutics Inc., a Celgene Company and Managing Director at Juno Therapeutics GmbH, and joined Juno through the acquisition of Stage Cell Therapeutics in May 2015. Dr. Germeroth has over 25 years of management experience in biotechnology. Dr. Germeroth served as the CEO at IBA GmbH and the COO at Stage Cell Therapeutics GmbH, and served eight years as CEO in three different German Biotech companies (Jerini BioTools GmbH, Chemotopix GmbH, Cytos Proteome Therapeutics GmbH) and as Chief Business Officer at Cytos Biotechnology AG in Switzerland. Dr. Germeroth studied chemistry in Frankfurt/Main and obtained his PhD in Biochemistry in the department of Nobel Prize Laureate Professor Hartmut Michel at the Max-Planck Institute of Biophysics in Frankfurt.

Gary Pigeau
Director, Centre for Advanced Therapeutic Cell Technologies
GE Healthcare Life Sciences

Gary Pigeau received his PhD in Biotechnology from Brock University in St. Catharines, Ontario. He completed a postdoctoral fellowship at the University of Alberta with a visiting scientist appointment at the University of Oxford. Gary moved to private industry in 2008, where his research group focused on process development and scale-up of a proprietary bioprocess technology. He then moved to commercial, large-scale biomanufacturing in 2013. Gary joined the Centre for Advanced Therapeutic Cell Technologies (CATCT), a collaboration between GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM), in 2016. He currently serves as Director of the CATCT facility in Toronto, Ontario. In this role, Gary focuses on biology support for new product introductions, internal technology development projects, and contract process development services for cell and gene therapy.

Day Two

Wednesday 26th February 2020

9:00 am | CAR T Therapies: Process Development and Manufacturing Readiness

Michael Leek

Chief Executive at TC BioPharm, Michael has 28 years’ experience in regenerative medicine, during which he progressed 9 different cell-based products from laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture, clinical, regulatory and logistic expertise, he has directly raised over £50m in equity and grant funding.

Michael Lehmicke
Director, Science & Industry Affairs
Alliance for Regenerative Medicine

Michael Lehmicke,  ARM's Director of Science and Industry Affairs, is responsible for shaping and leading science and manufacturing initiatives at ARM, as well as leading ARM’s science and technology-related member committees and task forces. Michael has more than 20 years of R&D experience in biomaterials, medical devices and regenerative medicine. He has led product development teams for class II devices, human cell and tissue-based products, and drug/device combination products. He is a creator and an inventor with multiple U.S. patents to his name. Michael has a MSc in Biomedical Engineering, with a focus on tissue engineering, from Drexel University.

Gisèle Deblandre

Gisèle Deblandre, PhD, is Chief Scientific Officer at MaSTherCell. She is an experienced cell and developmental biologist with extensive experience in cell therapy. She has worked for the last 8 years at MaSTherCell (Belgium) where she has been heading work on process and analytical assay development for cell and gene therapies at all phases of their clinical development. She has also set up and headed Project Management to support technology transfer and GMP manufacturing. Previously with Celyad (Belgium) she headed the development of an autologous cell therapy for the treatment of heart failure and at the laboratory of Paediatric Hepatology at the University of Leuven, the development of a hepatic progenitor-based therapy for liver diseases. Her career spans 22 years in R&D in life sciences, with a strong expertise in cell biology and mechanisms of cell differentiation. She has a PhD in Molecular Cell Biology from the University of Brussels and she then specialized in Developmental Biology at the Salk Institute (San Diego, California).

Stefan Ibing
Attorney at Law
Head of Legal CEE Pharma

Lead lawyer and member of the management-team of Novartis Pharma Services AG: - legal entity which exports the Rx-drugs of Novartis´ Innovative Medicines Division (Pharmaceuticals and Oncology) out of Switzerland into more than 80 countries worldwide by export-sales to 3rd party distributors. Furthermore this entity operates app. 35 Representative Offices. - main geographic areas: Eastern Europe (incl. small EU-countries), Middle East, Africa and Asia - started supporting this export-entity in 2012 as dedicated Senior Legal Counsel without direct reports, gradually built up a new operational legal department for this entity with currently 5 lawyers and a paralegal as direct reports - general-counsel-like scope of activities, including all major commercial contracts, country-setup analyses, investigations, market access topics, launch of Novartis` gene therapies in EU-countries (e.g. Kymriah CAR-T therapy and Luxturna) etc. - very close interactions and teamwork with a network of regional and cluster lawyers for the geographies Eastern Europe, Middle East, Africa and Asia.

Kamal Veer Saini
Senior Medical Director, Oncology

►           Kamal Veer Saini, a board-certified medical oncologist, is a Senior Medical Director, Oncology at Covance. He is based in Brussels, Belgium, and contributes to medical strategy in the oncology area and client engagement on asset development and all related aspects of medical and scientific execution. ►           He has more than 15 years of experience in academia and industry, having held numerous posts of increasing seniority across all phases of clinical drug development in various cancer types (solid tumors as well as hematological malignancies) with both regional and global responsibility. His publications include numerous articles in the areas of breast cancer, clinical trials, molecular oncology, biomarkers, global oncology, policy, etc.. ►           Areas of interest: Immuno-oncology, cell and gene therapy, global strategic clinical drug development, breast cancer, lung and other thoracic cancers, molecularly defined cancers, biomarkers, artificial intelligence in oncology.

Qasim Rafiq
Associate Professor, Cell & Gene Therapy Bioprocessing
University College London

Dr Qasim Rafiq is an Associate Professor at University College London in Cell and Gene Therapy Bioprocessing. He is a multidisciplinary engineer and currently leads a research portfolio of >£3M focusing on the bioprocessing, automation and biomanufacture of ATMPs. . He has specific interest in addressing the large-scale manufacturing challenges and enhancing process and product understanding to enable successful translation from the laboratory to the clinic. He is both a Chartered Engineer (CEng) and Chartered Scientist (CSci) and sits on multiple scientific and engineering committees including the BIA’s Cell and Gene Therapy Advisory Committee and the BSI’s Biotechnology Standards Group.

Reuben Benjamin
Consultant Haematologist
Kings College Hospital NHS

Lead lawyer and member of the management-team of Novartis Pharma Services AG:

  • legal entity which exports the Rx-drugs of Novartis´ Innovative Medicines Division (Pharmaceuticals and Oncology) out of Switzerland into more than 80 countries worldwide by export-sales to 3rd party distributors. Furthermore this entity operates app. 35 Representative Offices.
  • main geographic areas: Eastern Europe (incl. small EU-countries), Middle East, Africa and Asia
  • started supporting this export-entity in 2012 as dedicated Senior Legal Counsel without direct reports, gradually built up a new operational legal department for this entity with currently 5 lawyers and a paralegal as direct reports
  • general-counsel-like scope of activities, including all major commercial contracts, country-setup analyses, investigations, market access topics, launch of Novartis` gene therapies in EU-countries (e.g. Kymriah CAR-T therapy and Luxturna) etc.
  • very close interactions and teamwork with a network of regional and cluster lawyers for the geographies Eastern Europe, Middle East, Africa and Asia.

Tol Trimborn

Experienced Venture Partner with a demonstrated history of working in the venture capital and private equity industry. Strong information technology professional skilled in Business Development, Cell Biology, Biotechnology, Business Strategy, and Biochemistry.

William Cao

Dr. Wei (William) Cao is the founder, chairman and CEO of Gracell Biotechnologies Group. Through external partnership and in-house R&D effort, Gracell has been rapidly progressing with novel CAR-T programs and regenet stove medicine programs. Dr. Cao has over 30 years of professional experience in scientific research, products development and startups. He was the co-founder and CEO of a Nasdaq listed cellular therapy company. Prior to his ventures, Dr Cao served as Technical Manager for Bayer Asia Pacific, and China General Manager of Affymetrix, a world leader in genetic analysis. Dr. Cao earned a Bachelor’s degree in Medicine from Fudan University and a PhD degree in Immuno-Pharmacology from Medical College of Virginia. He has extensive research experience in immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. He is the inventor of more than 70 patents in the field of stem cell and CAR-T technologies.

Yannick Bulliard
Director, Translational Development

In 2016, Yannick Bulliard joined Immatics US, Inc. as Director Product Science, where he established the Department’s core activities in process development, development of immunoassays and quality control. Since 2017, Dr. Bulliard is leading the translational development of ACTallo®, Immatics’ allogeneic cellular therapy platform based on γδ T cells. Prior to Immatics, Dr. Bulliard was a project lead for several preclinical assets in Immuno-Oncology at Amgen, CA. He obtained his Ph.D. from the EPFL, Switzerland and went on to pursue a postdoctoral fellowship at Novartis in Cambridge, MA.

Aura Mackenzie
Senior Director, AVES, Market Access
bluebird bio

After over a decade in global pricing and market access consulting for biotech and big pharma, Aura shifted industry-side after realizing that nothing fired her up more in drug development than the promise of cell and gene therapy. Aura’s role at bluebird is early evidence and access strategy planning for the oncology and severe genetic disease portfolio.  Fun fact: Aura is a dab hand at ultimate frisbee and plays nearly every weekend, rain, snow, or shine. While she’s not as competitive as she once was, her vacations are still planned around frisbee tournaments more often than they’re not!

Valeria Judkowski
Senior Director, Quality Assurance, Site Qualification
Kite, a Gilead Company

Valeria Judkowski is the Senior Director, Quality Assurance, Site Qualification at Kite, a Gilead Company. In this role, she oversees the European regional team responsible of the commercial qualification of apheresis and treatment centers to work with Yescarta®, one of the first CAR T therapies to be developed, manufactured and commercialized. Prior to Kite, Valeria oversaw the areas of technology transfer, GMP manufacturing and quality control for a phase III autologous dendritic cell based therapy as part of the Immunocellular Therapeutics Ltd pipeline in Europe. In previous years, Valeria was an Assistant Professor in Immunology at The Torrey Pines Institute for Molecular Studies, La Jolla, California. She focused most of her scientific career on the field of Antigen Discovery, working mainly on the regulation of the T cell immune response for the development and evaluation of active immunotherapies in Oncology and Autoimmunity. Valeria studied at the University of Sciences of Buenos Aires, Argentina, from which she received a Master Degree in Molecular Biology and a PhD in Immunology.

Pippa Gledhill
Research Analyst
Beacon Targeted Therapies

Day Two

Wednesday 26th February 2020

10:00 am | CAR-TCR Landscape Review

Jingyi Xiang
Director of Scientific Alliances
Eureka Therapeutics

Jacob Plieth
Senior Reporter
Vantage Analysis

Jacob has 21 years' experience of writing about healthcare, and joined Vantage in 2012 from Edison Investment Research, where he spent five years as an equity research analyst.

He has also worked at Dow Jones and the Wall Street Journal. A biochemist by training, Jacob has spoken about pharmaceuticals and other topics on the BBC World Service and News 24, as well as contributing to various publications including Investors Chronicle and Mednous.

Day One

Tuesday 25th February 2020

8:30 am | Industry Leader's Fireside Chat

Anil Singhal
President & CEO
Adicet Bio

Dr. Singhal has served as Adicet Bio’s President and Chief Executive Officer and a member of the Board of Directors since May 2019. He joined Adicet from Canaan Partners where he served as Executive in Residence and OncoResponse Inc., where he served as Chief Scientific Officer. He is the former Vice President of Early Oncology Development of AbbVie and Head of their Abbvie-Redwood City, California site. During his tenure at AbbVie, he oversaw the global regulatory approval of Empliciti in multiple myeloma. As a member of the R&D leadership team, he helped to guide an impressive portfolio and key translational science capabilities in oncology and other diseases. Dr. Singhal has held senior roles in the U.S., Japanese and German biopharma/biotechnology industry leading to the approvals of Prosorba in auto-immune disease and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington. He serves on the Board of Directors of TriSalus Inc.

Richard Zajicek
Medicine and Process Delivery Leader

Omar Ali
Visiting Lecturer, Value Based Pricing & Former Adviser to NICE
University of Portsmouth

Qualified with a hospital pharmacy background, Omar has been working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust for over 15 years, sitting on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network. Omar has been a visiting Lecturer at UCLH Pharmacy Programme and was both Lecturer & Examiner on the Independent Prescribing V300 Course at the University of Surrey and has over 30 publications to date. He has been appointed as Visiting Lecturer on Value Based Pricing & Innovative Contracting at the University of Portsmouth, was an Editorial Content Adviser to Guidelines, and has  recently been invited to the position of Associate Editor to the Canadian Journal of Population Therapeutics & Clinical Pharmacology.

Vicki Coutinho
VP, Regulatory Affairs & Quality
GammaDelta Therapeutics

Manel Juan
Head of Immunotherapy Platform
Barcelona Children's Hospital and Hospital Clinic

Andre Choulika

Day One

Tuesday 25th February 2020

8:30 am | Industry Leader's Fireside Chat

Eric Alonzo
Senior Scientist, Cell Analytics
bluebird bio

Michal Besser
Head of Laboratory, Director
Sheba Medical Center

Zhifen Yang
Senior Scientist
Refuge Biotech

Day Two

Wednesday 26th February 2020

9:45 am | Contextual Regulation of CAR T Function In Vivo

Stefano Baila
Director of Operations and Business Development

Dalip Sethi
Manager, Senior Scientist, Cell Therapy Technologies
Terumo BCT

Dalip Sethi currently serves as the scientific development lead for the Cell Therapy Technologies portfolio at Terumo BCT. He holds a doctorate degree and conducted post-doctoral studies at Thomas Jefferson University, School of Medicine. Prior to Terumo BCT, Dalip was engaged in the development of technologies & methods for use in autologous cell therapy applications. Throughout his career, Dalip has authored multiple scientific publications and is a co-inventor on several patents & patent applications.

Day One

Tuesday 25th February 2020

9:30 am | Driving Automation in Cell Therapy Manufacturing

Nicolas Danzenbaecher
Senior Product Manager
Miltenyi Biotec

Will Singleterry
Director, Collaborations, Cancer Immunology Team

Fiona Thistlethwaithe
Medical Oncology Consultant & Director

Lindsey Clarke
Head of Cell & Gene Therapy EMEA
Bio-Techne Corporation

Mark Flower
VP, Business Development
Be The Match BioTherapies®

Oezlem Anak
VP,  Global Program Head CAR-T

Helen-Tayton Martin

Dr. Helen Tayton-Martin has served as our Chief Business Officer since March 2017, having formerly served as our Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. As our CBO, Dr. Tayton-Martin is responsible for optimizing the strategic and commercial opportunity for Adaptimmune’s assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company’s strategic partnership with GlaxoSmithKline (LSE/NYSE: GSK) (“GSK”).

Day One

Tuesday 25th February 2020

8:30 am | Industry Leader's Fireside Chat

Peggy Sotiropoulou
Director, Research & Development

Peggy Sotiropoulou joined Celyad in 2017. As Director of the R&D department, she leads a broad-ranging internal research program that aims to develop new strategies in CAR T cell design to target haematological and solid malignancies. Prior to Celyad, Peggy spent 17 years in Academic research in oncology and immunooncology. Before moving to industry, Peggy was associate Professor in the Université Libre de Bruxelles, in Brussels, Belgium, leading research in fundamental oncology and published landmark papers in top tier scientific journals. The aim of Peggy in Celyad is to translate cutting-edge research and innovation into actual treatments for patients.

Michael Koslowski
GammaDelta Therapeutics

Michael joined GammaDelta in 2018 from Mission Therapeutics where he was EVP Research & Development and Chief Medical Officer, responsible for developing Mission’s pipeline of deubiquitinating enzyme inhibitors. Prior to joining Mission Therapeutics Michael was VP Clinical Sciences & Early Development at Glenmark Pharmaceuticals where he led all clinical activities to progress Glenmark’s innovative drug portfolio. Before, Michael formed and managed a new group of Translational Medicine Experts at Boehringer Ingelheim to support and drive early drug development activities across all therapeutic areas at BI. Michael was Group Leader New Targets & Antibody Development at Ganymed Pharmaceuticals and a Principal Scientist in Experimental & Translational Oncology at the University of Mainz with focus on cancer drug target identification and development of novel immunotherapeutics.

Day One

Tuesday 25th February 2020

8:30 am | Industry Leader's Fireside Chat

Mythili Koneru
SVP, Clinical Development
Marker Therapeutics

Mythili Koneru, M.D., Ph.D. is Senior Vice President of Clinical Development at Marker Therapeutics, a clinical-stage company specializing in the development of T cell-based immunotherapies for treatment of hematological malignancies and solid tumors. In this role, she is responsible for clinical development strategy, clinical study design, and medical oversight of the Company's therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology. In her previous role, Dr. Koneru designed early-stage clinical trials for hematologic and solid tumor malignancies and was instrumental in developing clinical trial protocols, serving as medical lead for trial conduct. Prior to Eli Lilly, Dr. Koneru completed her oncology fellowship in the laboratory of Dr. Renier Brentjens at Memorial Sloan-Kettering Cancer Center, where she developed adoptive T cell therapies in both leukemia and solid tumor malignancies in early phase clinical trials.

Jo Tomlins
Clinical Services Manager/ Nurse Clinician
The Christie NHS Foundation Trust

Jo Tomlins (RN, BSc (Hons), MSc, NMP) has worked as a Nurse Clinician in haematology oncology since qualifying as an advanced nurse practitioner in 2008. In 2015 she took on a combined role as Nurse Clinician and Clinical Services Manager for haematology, teenage and young adults (TYA) and endocrinology and maintained a clinical focus on acute lymphoblastic leukaemia and haematological malignancies in TYA patients. Jo has worked at the Christie since 2002 in haematology as a ward nurse and subsequently research/specialist nurse prior to doing her masters in advanced practice. Jo has an in depth knowledge of haematological malignancies and uses advanced clinical skills in the management of patients. Jo is also the clinical lead on both the principles of haematology oncology and CART masters modules at The University of Manchester where she is an honorary clinical fellow. As an experienced haematology nurse and clinical services manager Jo has delivered on several service developments such as setting up ambulatory care and more recently CART therapy for this patient group.  She is driven to provide high quality care to oncology patients through her clinical, education and leadership roles.

Kimberly Freeman
Vice President, Global Commercial Head, Commercial Strategy

Kimberly Freeman is the Vice President, Global Commercial Head, Commercial Strategy at Adaptimmune LLC, a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. Kimberly joined Adaptimmune in 2016 to lead global commercial strategy and market preparation for the successful development and regulatory approval of these novel therapeutics. Specializing in oncology drug development and commercialization for over 25 years, Kimberly has worked within the biopharmaceutical industry in disciplines across research, clinical development, new product planning, marketing, sales and market access. Previously she served as head of Oncology National Accounts at Boehringer Ingelheim Pharmaceuticals where she launched their first lung cancer product and companion diagnostic. Prior to that, she spent 14 years at GlaxoSmithKline where she launched five unique oncology products, including treatments for solid tumors and hematologic malignancies, as well as supportive care agents. Kimberly holds a master’s degree in Biology from Cornell University.

Scott Carter
VP, Field Operations and Customer Relations

Cindy Jung
Director of Vector Process Development in the Cell and Gene Therapy Platform

Cindy Jung is the Director of Vector Process Development in the Cell and Gene Therapy Platform at GSK, and is responsible for developing robust and scalable viral vector manufacturing processes.  Cindy has previously held roles at GSK leading teams that focused on alternative manufacturing processes for biopharms, and at Merck supporting downstream development of viral vaccines.  She obtained her Ph.D. in Biomedical Engineering from the joint program at Georgia Tech and Emory University.

Lisa Kinsella
Head Legal Biologics, Cell & Gene

Lisa Kinsella is Head Legal Biologics, Cell & Gene at Novartis Technical Operations, and provides legal support for all aspects of manufacturing, supply chain, quality and technical development of biologics and advanced therapies.  Lisa joined Novartis in 2012 and since then has held positions of increasing responsibility within Novartis Legal. Prior to joining Novartis, Lisa practiced law in the life sciences practice of Arthur Cox, one of Ireland’s leading commercial law firms where she advised clients in the pharmaceutical, biotech and medical devices fields on transactional, regulatory and commercial contracting matters. Lisa is qualified in Ireland, England & Wales and is admitted to the New York Bar.

Steven Shamah
Senior Vice President and Head of Research
Obsidian Therapeutics

Dr. Steven Shamah joined Obsidian Therapeutics in September 2016 as Senior Vice President and Head of Research where he leads a dynamic team towards the discovery and development of next generation cell and gene therapeutics.  Previously, Steve served as Head of Scientific Operations for the Cell and Protein Sciences group at Juno Therapeutics and, prior to that, as VP of Cell Biology at X-Body Biosciences.  In addition, Steve has served in various management and scientific leadership roles at SRU Biosystems, Archemix, Hydra Biosciences and Phylos, with a particular focus on biologics discovery using in vitro display technologies.

Ryan Cawood
Founder and CEO
Oxford Genetics

Ryan founded the company in 2011 with the aim to revolutionize DNA design, optimisation and assembly to enable molecular engineering to fulfil its promise in synthetic biology and medicine. Ryan has a first class degree in Genetics and a Ph.D. from Oxford University. He is an experienced genetic engineer with extensive knowledge and practical insight working with bacterial, botanical and mammalian recombinant expression systems. Ryan's research interests in synthetic biology and molecular engineering include vaccines and treatments for infectious diseases and cancer. He was inspired to create Oxford Genetics after observing that inefficient DNA design and assembly often limit scientific progress.

Laurence Cooper
Ziopharm Oncology

Laurence joined Ziopharm Oncology as chief executive officer in 2015 after Ziopharm and Intrexon Corporation together licensed technology for a non-viral approach for genetically modifying T cells from MD Anderson Cancer and the University of Minnesota. This technology is designed to reduce the cost and complexity of genetically modified T cells. Prior to joining Ziopharm, Laurence was a tenured Professor at MD Anderson with joint appointments in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children’s Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. He remains a visiting scientist at MD Anderson. Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and he completed his training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

Marleen Van Loenen
Director, Non-Clinical Development

I am responsible to manage and oversee non-clinical development of TEGs: abT cells engineered to express a defined gamma/delta TCR. Gadeta's preclinical engine encompasses different in vitro and in vivo models using tumor and healthy cell lines as well as primary material to test Gadeta's lead product TEG002 as well as new leads for safety and efficacy. Results are written into study reports, to enable IND submission. To optimize and speed up preclinical development, I oversee collaborations with companies and universities to exchange knowledge, models and materials. Furthermore, I am on two Joint Project Teams (Research & Translational Science) with collaborator Kite.